EZH2 regulates pancreatic cancer cells through E2F1, GLI1, CDK3, and Mcm4
Hongfeng Li,
Hailong Wang,
Yunlong Cui,
Wenhua Jiang,
Hongjie Zhan,
Lixia Feng,
Mingyou Gao,
Kuo Zhao,
Limeng Zhang,
Xiaojing Xie,
Ning Zhao,
Ying Li,
Pengfei Liu
Affiliations
Hongfeng Li
Department of Clinical Laboratory, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
Hailong Wang
Department of Oncology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
Yunlong Cui
Department of Hepatobiliary Oncology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital
Wenhua Jiang
Department of Radiotherapy, The Second Hospital of Tianjin Medical University
Hongjie Zhan
Department of Gastric Cancer, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital
Lixia Feng
Department of Nursing, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Konggang Hospital
Mingyou Gao
Department of Oncology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital
Kuo Zhao
Department of Oncology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital
Limeng Zhang
Department of Oncology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital
Xiaojing Xie
Department of Oncology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital
Ning Zhao
Department of Oncology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital
Ying Li
Department of Medical Oncology, The Fourth Hospital of Hebei Medical University
Pengfei Liu
Department of Oncology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
Abstract Pancreatic cancer (PC) is one of the most common malignant tumors in digestive tract. To explore the role of epigenetic factor EZH2 in the malignant proliferation of PC, so as to provide effective medical help in PC. Sixty paraffin sections of PC were collected and the expression of EZH2 in PC tissues was detected by immunohistochemical assay. Three normal pancreas tissue samples were used as controls. The regulation of EZH2 gene on proliferation and migration of normal pancreatic cell and PC cell were determined by MTS, colony forming, Ki-67 antibody, scratch and Transwell assays. Through differential gene annotation and differential gene signaling pathway analysis, differentially expressed genes related to cell proliferation were selected and verified by RT-qPCR. EZH2 is mainly expressed in the nuclei of pancreatic tumor cells, but not in normal pancreatic cells. The results of cell function experiments showed that EZH2 overexpression could enhance the proliferation and migration ability of PC cell BXPC-3. Cell proliferation ability increased by 38% compared to the control group. EZH2 knockdown resulted in reduced proliferation and migration ability of cells. Compared with control, proliferation ability of cells reduced by 16%-40%. The results of bioinformatics analysis of transcriptome data and RT-qPCR demonstrated that EZH2 could regulate the expression of E2F1, GLI1, CDK3 and Mcm4 in normal and PC cells. The results revealed that EZH2 might regulate the proliferation of normal pancreatic cell and PC cell through E2F1, GLI1, CDK3 and Mcm4.
